Last reviewed · How we verify

Welbutrin XL — Competitive Intelligence Brief

Welbutrin XL (Welbutrin XL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Norepinephrine-dopamine reuptake inhibitor (NDRI). Area: Psychiatry / Neurology.

marketed Norepinephrine-dopamine reuptake inhibitor (NDRI) Norepinephrine transporter (NET) and dopamine transporter (DAT) Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Welbutrin XL (Welbutrin XL) — Massachusetts General Hospital. Wellbutrin XL is a norepinephrine-dopamine reuptake inhibitor (NDRI) that increases levels of norepinephrine and dopamine in the brain by blocking their reuptake at the neuronal synapse.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Welbutrin XL TARGET Welbutrin XL Massachusetts General Hospital marketed Norepinephrine-dopamine reuptake inhibitor (NDRI) Norepinephrine transporter (NET) and dopamine transporter (DAT)
Switch to bupropion Switch to bupropion Centre for Addiction and Mental Health marketed Norepinephrine-dopamine reuptake inhibitor (NDRI) Norepinephrine transporter (NET); Dopamine transporter (DAT)
BuproprionSR BuproprionSR National Institute of Mental Health (NIMH) marketed Norepinephrine-dopamine reuptake inhibitor (NDRI) Norepinephrine transporter (NET) and dopamine transporter (DAT)
generic bupropion generic bupropion University of Michigan marketed Norepinephrine-dopamine reuptake inhibitor (NDRI) Norepinephrine transporter (NET); Dopamine transporter (DAT)
bupropion extra long (XL) bupropion extra long (XL) New York State Psychiatric Institute marketed Norepinephrine-dopamine reuptake inhibitor (NDRI) Norepinephrine transporter (NET), dopamine transporter (DAT)
Active bupropion, No counseling Active bupropion, No counseling University of Wisconsin, Madison marketed Norepinephrine-dopamine reuptake inhibitor (NDRI) Norepinephrine transporter (NET) and dopamine transporter (DAT)
Bupropion Hydrochloride Controlled-release Bupropion Hydrochloride Controlled-release University of Rochester NCORP Research Base marketed Norepinephrine-dopamine reuptake inhibitor (NDRI) Norepinephrine transporter (NET) and dopamine transporter (DAT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Norepinephrine-dopamine reuptake inhibitor (NDRI) class)

  1. University of Wisconsin, Madison · 2 drugs in this class
  2. Massachusetts General Hospital · 1 drug in this class
  3. National Institute of Mental Health (NIMH) · 1 drug in this class
  4. New York State Psychiatric Institute · 1 drug in this class
  5. University of Michigan · 1 drug in this class
  6. University of Rochester NCORP Research Base · 1 drug in this class
  7. University of Texas Southwestern Medical Center · 1 drug in this class
  8. Centre for Addiction and Mental Health · 1 drug in this class
  9. Washington University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Welbutrin XL — Competitive Intelligence Brief. https://druglandscape.com/ci/welbutrin-xl. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: